Is there an association of progesterone (P 4 ) on the day of trigger with live birth in autologous ART transfer cycles on day 5 versus day 6? SUMMARY ANSWER: P 4 had a greater negative effect on live birth in day 6 fresh transfers compared to day 5 fresh transfers.
Introduction
Studies have demonstrated lower pregnancy rates in ART cycles where embryos grow more slowly (Lewin et al., 1994; Shapiro et al., 2001) . A slow growing embryo may be an indicator of reduced embryo quality or embryo aneuploidy (Lewin et al. 1994; Su et al., 2016) . It may also lead to increased embryo-endometrial asynchrony (Van Voorhis and Dokras, 2008) , leading to reduced implantation, despite using a competent embryo. Shapiro et al. demonstrated reduced pregnancy rates in fresh ART cycles when embryos blastulated on day 6 compared to embryos that blastulated on day 5 (Shapiro et al., 2008) . However, when frozen embryo transfer (FET) cycles were analyzed, there was no difference in pregnancy rates between day 5 and day 6 blastocysts (Richeter et al., 2006) . Richter et al. also demonstrated similar pregnancy rates in frozen-thawed cycles where blastulation occurred on day 5 compared to day 6 (Richter et al., 2006) . This discrepancy in pregnancy rates in fresh versus FET cycles among day 5 and day 6 blastocysts suggests endometrial asynchrony may play a large role in the reduction in fresh pregnancy rates of day 6 embryos transfers.
Premature progesterone (P 4 ) elevation has been shown to reduce fresh ART pregnancy rates (Bosch et al., 2010; Xu et al., 2012; Venetis et al., 2013; Hill et al., 2015; Connell et al., 2016; Healy et al., 2016) . This negative effect is due to premature advancement of the endometrium with demonstrable changes in gene expression (Labarta et al., 2011; Van Vaerenbergh et al., 2011) , which decouples the natural embryo-endometrium synchrony driven by the LH surge. This negative effect of premature P 4 elevation may be mitigated by FET cycles, where the effect of the increased P 4 levels from the oocyte retrieval cycle seemingly does not have an effect in the subsequent FET cycle (Shapiro et al., 2010; Yang et al., 2015; Healy et al., 2016) .
Premature P 4 elevation has been shown to decrease live birth in both cleavage and blastocyst transfer cycles (Hill et al., 2015) , but it is unclear if the effect of premature P 4 elevations is similar on day 5 and day 6 embryo transfer cycles. Theoretically, a slow growing embryo and an advanced endometrium should have a compounding negative effect, widening the embryo-endometrial asynchrony (Franasiak et al., 2016) . The objective of this study was to evaluate the association of P 4 on the day of trigger with live birth in fresh ART transfer cycles on day 5 versus day 6.
Materials and Methods

Study design
This was a retrospective cohort analysis of fresh autologous and FET ART cycles from 2011 to 2014. Two primary analyses were performed. The fresh cycles were analyzed to examine the effect of premature P 4 elevations on live birth in day 5 versus day 6 embryo transfer cycles. To separate out the potential effect of embryo-endometrial asynchrony from effects of poor embryo quality in day 6 embryos, a secondary analysis was performed. This evaluated FET cycles where serum P 4 was obtained on the day of ovulation trigger in the original fresh cycle. Any effects of poor embryo quality should carry over into subsequent FET cycles, whereas effects of embryo-endometrial asynchrony would not carry over.
Ethical approval
The study was performed at Shady Grove Fertility Reproductive Science Center in Rockville, MD, USA, and was approved by the Institute Review Board. Informed consent was not required.
Patients
All patients who underwent a fresh or frozen autologous embryo transfer during the periods in which serum progesterone levels were measured on the day of ovulation trigger were included in the analysis. Exclusion criteria were donor oocyte cycles, no embryo transfer cycles, Day 3 embryo transfer cycles, and pre-genetic screening cycles.
Stimulation protocol
Ovarian stimulation utilized mixed FSH/LH protocols under GnRH antagonist or GnRH agonist pituitary suppression (Stillman et al., 2009) . In general, oral contraceptive treatment was initiated 21 days prior to stimulation. For GnRH antagonist cycles, the antagonist (Ganirelix® 250 mcg daily, Organon) was initiated when the lead follicle was 14 mm in size. For GnRH agonist cycles, 20 units of leuprolide acetate (Lupron®, Abbott Pharmaceutical Products, USA) was initiated during the last 3 days of oral contraceptives. The leuprolide acetate dose was decreased to 5 units when ovarian suppression was confirmed. Ovarian stimulation was achieved by employing recombinant FSH and hMG. When the lead follicle was ≥18 mm, final oocyte maturation was triggered with 10 000 IU of hCG or with 4 mg of GnRH agonist (Lupron®). Serum progesterone levels were obtained on this day of trigger. Oocyte retrieval occurred 36 h later and insemination was achieved with conventional IVF or ICSI as clinically indicated.
Ultrasound guided embryo transfer was performed on day 5 or day 6. Typically, embryo transfers would occur on day 5, unless no embryos had developed to the blastocyst or early blastocyst stage. In these cases, embryos were cultured to day 6 to allow for further embryo development to assist in embryo selection for transfer. Embryos were graded as good, fair or poor according to the simplified Society for Assisted Reproductive Technology (SART) scoring system (Heitmann et al., 2013) . Luteal support was given consistently with progesterone supplementation. Serum hCG levels were assessed 2 weeks after the ovulation trigger injection and ultrasonographic confirmation of pregnancy was obtained in all pregnant patients.
Embryo cryopreservation and thawing were performed via a vitrification-warming method. For endometrial preparation in FET cycles, patients underwent ovarian and uterine suppression using combined hormonal oral contraceptive pills. After a baseline hormone assessment and a transvaginal ultrasound to document no functional ovarian cysts and a thin endometrium, the patients were started on i.m. estradiol valerate at 4 mg every third day. When the serum estradiol level had reached >200 pg/ml and the endometrial thickness was >8 mm on transvaginal ultrasound, the patients were started on 50 mg daily of i.m. progesterone in oil. Day 5 and 6 frozen embryos were both thawed after 5 days of progesterone supplementation and transferred on the sixth day.
Serum progesterone levels were measured using a solid-phase, competitive chemiluminescent enzyme immunoassay (Immunolyte 2000 Progesterone assay, Siemens Medical Solutions Diagnostic, PA, USA). The lower limit of detection for the assay was 0.2 ng/ml and the analytical sensitivity of the assay was 0.1 ng/ml. Intra-assay and inter-assay coefficients of variances were 6.7% and 7.2%, respectively. During the study, there were no changes in the P 4 assay. The assay was utilized as a routine part of clinical care and was run daily, without freezing for batching. The laboratory regularly performed calibration verifiers (linearity) during the study period. Assay precision was monitored with three levels of control, with progesterone control samples from a third party (Bio-Rad Laboratories). Quality controls were run at the beginning of the assay run. Specifically, the three levels of concentration controls were as follows: low value mean 0.67 ng/ml (0.47-0.87 ng/ml), middle value mean 7.18 ng/ml (6.38-7.98 ng/ml), and high value mean 19.9 ng/ml (17.1-22.7 ng/ml). Standard curves were run in triplicate and samples were measured a single time (not in duplicate).
Outcomes
The primary outcome was live birth, defined as a live born baby at 24 weeks gestation or later.
Statistics
Generalized estimating equations (GEE) were used to evaluate the association of P 4 with live birth. GEE models compared day 5 versus day 6 transfers in both the fresh and FET cycle cohorts. GEE modeling accounted for patients with multiple cycles and for confounding variables. Confounding variables with a significant association with live birth in univariate models (P < 0.05) were included in adjusted multivariate models: age, BMI, primary diagnosis, stimulation protocol, trigger medication, endometrial thickness, peak estradiol, number of oocytes retrieved, number of embryos transferred, embryo stage, embryo quality and the number of supernumerary embryos for vitrification. GEE models were used to perform interaction testing to determine if the effect of P 4 on live birth was similar in day 5 and day 6 transfers. P 4 was treated as both a continuous variable and a threshold variable ≥1.5 ng/ml. In these analyses, P 4 was treated as a dichotomous variable, evaluating live birth in day 5 and day 6 transfers with P 4 ≥ 1.5 ng/ml compared to FET cycles with P 4 < 1.5 ng/ml. The P 4 level of ≥ 1.5 ng/ml was chosen as a cut-off because a prior study demonstrated a negative effect on clinical pregnancy in ART cycles over this threshold (Bosch et al., 2010) . Clinical pregnancy in this prior study was defined as a viable fetus beyond 20 weeks gestation on ultrasound. Additional threshold analyses of day 5 versus day 6 fresh transfers were performed based on thresholds of 1.1 ng/ml derived from receiver operating characteristic (ROC) curves in this data set and 0.8 ng/ml from a large meta-analysis (Venetis et al., 2013) . GEE models were also used to compare cohorts with normal P 4 < 1.5 ng/ml versus those with elevated P 4 ≥ 1.5 ng/ml.
Live birth versus P 4 graphs were generated to visually demonstrate the effect of P 4 on outcomes using various arbitrary P 4 thresholds. For statistical analysis, the GEE models were used to examine the entire spectrum of P 4 data without artificial or arbitrary stratifications. Results were expressed as odds ratios (OR) with 95% CIs with P values <0.05 considered statistically significant. ROC curves were used to further estimate the effect of P 4 on day 5 versus day 6 transfers. Statistical analysis was performed using SPSS (IBM, Armonk, NY, USA).
Results
Fresh ART analysis
There were 4120 fresh day 5 transfers and 230 fresh day 6 transfers included in the study. Day 6 transfers were generally poorer prognosis cycles and were associated with older patients, more gonadotrophin usage, and fewer embryos for vitrification (Table I) . Median progesterone values were slightly higher, by 0.1 ng/ml in the day 6 cohort (P = 0.01). A value of P 4 ≥ 1.5 ng/ml occurred in 15% of day 5 transfers and 26% of day 6 transfers (P < 0.001). The likelihood of having a blastocyst stage embryo for transfer was 90.8% in the day 6 cohort versus 91.6% in the day 5 cohort (OR 0.97, 95% CI 0.60-1.57, P = 0.92). The likelihood of having an embryo graded as good available for transfer was lower in the day 6 cohort at 73.0% versus 83.3% in the day 5 cohort (OR 0.53, 95% CI 0.39-0.72, P < 0.001). There were statistically more embryos transferred in the day 5 cohort, although the mean difference was small at 0.12 embryos per transfer.
Elevated P 4 ≥1.5 ng/ml was associated with several stimulation parameters (Supplementary Table 1 ). Elevated P 4 was associated with higher doses of total gonadotrophins, higher serum estradiol, and more oocytes retrieved. Embryo parameters were similar in patients with normal and elevated P 4 , including having a good quality embryo to transfer, a blastocyst stage transfer, the number of embryos transferred, and the number of supernumerary embryos available for vitrification. Patients with elevated P 4 had a lower live birth rate (36.3% versus 46.7%, P < 0.001).
Live birth occurred less frequently in the day 6 cohort, at 34.0% versus 45.6% in the day 5 cohort (OR 0.67, 95% CI 0.56-0.80, P = 0.01) ( Table I ). The lower likelihood of live birth persisted when adjusted for age, the number of embryos transferred, the quality of the embryo and the stage of embryo development (OR 0.61, 95% CI 0.46-0.81, P = 0.01).
P 4 as a continuous variable was negatively associated with live birth in both cohorts (Fig. 1) . The negative association with P 4 was stronger in the day 6 cohort (OR 0.51, 95% CI 0.40-0.66) than in the day 5 cohort (OR 0.75, 95% CI 0.66-0.85). The negative effect of P 4 on both cohorts persisted in adjusted models controlling for confounding variables (Table II) . P 4 ≥ 1.5 ng/ml was negatively associated with live birth in both cohorts. In the day 5 cohort, live birth decreased from 47% when P 4 < 1.5 ng/ml to 37% when P 4 ≥ 1.5 ng/ml (P < 0.01) (Table III) . In the day 6 cohort, live birth decreased from 39% when P 4 < 1.5 ng/ml to 20% when P 4 ≥ 1.5 ng/ml (P < 0.01) (Table III) . Again, the negative association with P 4 was stronger in the day 6 cohort (OR 0.40, 95% CI 0.19-0.80) than in the day 5 cohort (OR 0.60, 95% CI 0.56-0.80) (not shown). The negative effect of P 4 on both cohorts persisted in adjusted models controlling for confounding variables. Similar findings were noted with additional threshold analysis conducted at 1.1 ng/ml and 0.8 ng/ml (Table III) . ROC curves demonstrated a higher AUC for P 4 predicting live birth in day 6 transfers (AUC 0.59, 95% CI 0.51-0.66) than in day 5 transfers (AUC 0.54, 95% CI 0.52-0.55). Interaction testing was statistically significant (P < 0.001), indicating the negative effect of P 4 on live birth was different between the two cohorts.
FET ART analysis
There were 468 FET day 5 transfers and 292 day 6 transfers included in the study. Live birth occurred in 39.9% of day 5 FET cycles and 33.2% of day 6 cycles. The likelihood of clinical pregnancy was similar between day 5 and 6 FET cycles in unadjusted and adjusted GEE models (OR 0.76, 95% CI 0.54-1.07, P = 0.12). There was no effect of P 4 on live birth in FET cycles in either day 5 or 6 FET cycles (Supplementary Figure 1) . When P 4 was ≥ 1.5 ng/ml in the oocyte retrieval cycle that generated the frozen blastocysts, live birth occurred in 36.5% of day 6 cycles and 37.5% of day 5 cycles (P = 0.98) (Supplementary Figure 1) . P 4 × day of transfer interaction testing was not statistically significant (P = 0.43), indicating that P 4 did not affect either day 5 or 6 transfers when they were FET cycles.
Discussion
These data demonstrated a negative association of P 4 on live birth in both day 5 and 6 embryo transfers. However, the negative association of P 4 was more pronounced in day 6 transfers. Further, day 6 fresh transfers had a greater reduction in live birth than day 5 fresh transfers when P 4 was elevated ≥1.5 ng/ml on the day of trigger. Finally, the differences between the groups did not persist into subsequent FET cycles. Overall, these data suggest that a slow growing embryo in the setting of premature progesterone elevations leads to a worsening of embryo-endometrial asynchrony.
These data are consistent with Shapiro et al. who demonstrated a 51% versus 33% clinical pregnancy rate in day 5 versus 6 fresh transfers (Shapiro et al., 2008) . Conversely, they found similar clinical pregnancy rates of 64% and 59% in FET cycles between the two groups (Shapiro et al., 2008) . Our study adds to this body of literature by investigating the role that premature P 4 elevation may have in explaining some of the difference between fresh day 5 and 6 transfers.
A weakness of these data is that ploidy status of the embryos was not examined with preimplantation genetic screening. Certainly if day 6 embryos are more likely to be aneuploid, then a reduction in live birth would be expected regardless of embryo-endometrial asynchrony. Taylor et al. reported higher aneuploidy in slower developing blastocysts, with 57% on day 6 versus 44% on day 5 (Taylor et al., 2014) . However, other studies have found no differences in aneuploidy based on day of blastulation (Kroener et al., 2012) . Embryo aneuploidy has been associated with slow cleavage (Magli et al., 2007) and it seems biologically plausible it could be associated with slow blastulation. Our study did demonstrate a 10% reduction in the likelihood of a patient having a morphologically good quality embryo to transfer if blastulation occurred on day 6. Thus, while embryo-endometrial asynchrony may explain a large portion of the reduction in live birth seen in slow developing embryos, it is likely that a decrease in embryo quality and an increase in embryo aneuploidy also play a role.
Another weakness of this paper is its retrospective design with the potential for undetected confounding variables. An example of such potential confounders is that this study lacked data on the thaw survival rates between day 5 and day 6 blastocysts. In our laboratory, thaw 
Table I
Baseline and stimulation characteristics of day 5 (n = 4120) and day 6 (n = 230) transfer cohorts. survival for day 5 and day 6 blastocysts is over 95% and the embryo quality of both day 5 and day 6 vitrified blastocysts was similar in this data set. For these reasons, survival discrepancy between the two cohorts was unlikely to bias the results, but this cannot be definitively ruled out with the retrospective design. Prior work has suggested that high responders are not affected by premature elevated P 4 (Griesinger et al., 2013) , although this protective effect has been challenged by others (Bosch, 2014; Hill et al., 2015) . While this data set did not contain a large enough sample size in fresh day 6 transfers to stratify the analysis by oocyte yield, this was accounted for by controlling for oocyte yield in the multivariate GEE analysis. Similarly, premature P 4 elevations vary based on GnRH antagonist versus agonist protocols, so this confounding variable was accounted for in multivariate GEE models. Although the data demonstrated live birth in FET cycles are not affected by the P 4 value from the fresh cycle in which those embryos were generated, this study design cannot prove that using FET as a treatment strategy for elevated P 4 is superior to a fresh transfer. RCTs are needed to answer these questions and, to our knowledge, only one study like this has been performed. In a RCT of 80 patients with elevated progesterone, Yang et al. demonstrated an 18.4% live birth rate in subjects randomized to fresh blastocyst transfer and 31.0% in subjects randomized to frozen-thaw transfer (P = 0.30) (Yang et al., 2015) . The lack of difference between the two groups could be due to the study being underpowered. Based on their results, 342 subjects would need to be randomized to have sufficient power to detect if FET is a successful treatment strategy for P 4 elevation.
Another weakness of this study and the current literature on premature progesterone elevation is the progesterone assay itself. The progesterone assay is primarily designed to detect ovulatory progesterone ranges. As such, the clinical use of narrow threshold ranges in the low progesterone range to define an abnormal test, such as 1.5 ng/ml, may not adequately discriminate all patients. In other words, the progesterone assay is not currently optimized to discriminate between patients with a progesterone of 1.5 versus 1.8 ng/ml. While these data and many others demonstrate a strong negative association of premature progesterone elevation with ART outcomes, there is a need for clinical utilization of progesterone assays designed to measure progesterone in the 0-3 ng/ml range. In the absence of such assays, prospective studies could limit this weakness with duplicate sample assessment and batching of samples, which was not done in this study due to the retrospective design.
Finally, this study evaluated progesterone as both a continuous variable and dichotomous variable. The threshold of 1.5 ng/ml was based on a large published data set (Bosch et al., 2010) ; however, data exist supporting threshold variables ranging from 0.8 to 3.0 ng/ml (Venetis et al., 2013) . This further highlights the technical and clinical limitations in interpreting the literature on premature progesterone elevations. However, it should be noted that the interaction test suggested that progesterone had a different association with live birth in day 5 versus day 6 fresh transfers, when progesterone was utilized as a continuous variable. Such an analysis is independent of any specific threshold utilization.
In conclusion, this study demonstrated that premature P 4 elevation has a negative association with live birth across both fresh day 5 and 6 embryo transfers, but the association is more marked when embryoendometrial asynchrony is worsened by a slow growing embryo. There is a need for large, RCTs to definitively demonstrate that freezing embryos and performing a subsequent transfer can ameriliorate the negative effect of elevated serum P 4 .
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